NCT05037149View on ClinicalTrials.gov

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

March 30, 2024

Study Completion Date

March 30, 2024

Conditions
Solid Tumor
Interventions
DRUG

STP707

STP707 Powder for Injection

Trial Locations (9)

30322

Emory University, Atlanta

32224

Mayo Clinic, Jacksonville

55905

Mayo Clinic, Rochester

78758

NEXT Oncology, Austin

80218

Sarah Cannon Research Institute at HealthONE, Denver

85054

Mayo Clinic, Phoenix

90033

USC Norris Comprehensive Cancer Center, Los Angeles

06511

Yale University, New Haven

07960

Atlantic Health System, Morristown

Sponsors

Lead Sponsor

Sirnaomics
All Listed Sponsors
lead

Sirnaomics

INDUSTRY

NCT05037149 - Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors | Biotech Hunter | Biotech Hunter